CN105744949A - 用c1-酯酶抑制剂治疗器官移植患者中的抗体介导的排斥的方法 - Google Patents

用c1-酯酶抑制剂治疗器官移植患者中的抗体介导的排斥的方法 Download PDF

Info

Publication number
CN105744949A
CN105744949A CN201480063697.5A CN201480063697A CN105744949A CN 105744949 A CN105744949 A CN 105744949A CN 201480063697 A CN201480063697 A CN 201480063697A CN 105744949 A CN105744949 A CN 105744949A
Authority
CN
China
Prior art keywords
inh
patient
organ
plasmapheresis
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480063697.5A
Other languages
English (en)
Chinese (zh)
Inventor
C·布鲁姆
M·E·尤克尼斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viropharma Holdings Ltd
Original Assignee
Viropharma Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52016153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105744949(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viropharma Holdings Ltd filed Critical Viropharma Holdings Ltd
Priority to CN202010018792.0A priority Critical patent/CN111388655A/zh
Publication of CN105744949A publication Critical patent/CN105744949A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480063697.5A 2013-11-22 2014-11-21 用c1-酯酶抑制剂治疗器官移植患者中的抗体介导的排斥的方法 Pending CN105744949A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010018792.0A CN111388655A (zh) 2013-11-22 2014-11-21 用c1-酯酶抑制剂治疗器官移植患者中的抗体介导的排斥的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361907550P 2013-11-22 2013-11-22
US61/907,550 2013-11-22
US201462029086P 2014-07-25 2014-07-25
US62/029,086 2014-07-25
PCT/US2014/066784 WO2015077543A1 (en) 2013-11-22 2014-11-21 Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202010018792.0A Division CN111388655A (zh) 2013-11-22 2014-11-21 用c1-酯酶抑制剂治疗器官移植患者中的抗体介导的排斥的方法

Publications (1)

Publication Number Publication Date
CN105744949A true CN105744949A (zh) 2016-07-06

Family

ID=52016153

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480063697.5A Pending CN105744949A (zh) 2013-11-22 2014-11-21 用c1-酯酶抑制剂治疗器官移植患者中的抗体介导的排斥的方法
CN202010018792.0A Pending CN111388655A (zh) 2013-11-22 2014-11-21 用c1-酯酶抑制剂治疗器官移植患者中的抗体介导的排斥的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202010018792.0A Pending CN111388655A (zh) 2013-11-22 2014-11-21 用c1-酯酶抑制剂治疗器官移植患者中的抗体介导的排斥的方法

Country Status (24)

Country Link
US (3) US9895428B2 (https=)
EP (3) EP4162947A1 (https=)
JP (5) JP6431912B2 (https=)
KR (2) KR102312817B1 (https=)
CN (2) CN105744949A (https=)
AU (2) AU2014352846B2 (https=)
BR (1) BR112016011499A2 (https=)
CA (1) CA2930964A1 (https=)
CY (1) CY1121298T1 (https=)
DK (1) DK3071219T3 (https=)
ES (1) ES2708655T3 (https=)
HR (1) HRP20190184T1 (https=)
HU (1) HUE041809T2 (https=)
LT (1) LT3071219T (https=)
ME (1) ME03318B (https=)
MX (2) MX378834B (https=)
NZ (2) NZ719724A (https=)
PL (1) PL3071219T3 (https=)
PT (1) PT3071219T (https=)
RS (1) RS58343B1 (https=)
SG (1) SG10201804326SA (https=)
SI (1) SI3071219T1 (https=)
SM (1) SMT201900042T1 (https=)
WO (1) WO2015077543A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113035369A (zh) * 2021-03-10 2021-06-25 浙江大学 一种肾移植抗感染药物剂量预测模型的构建方法
CN113194996A (zh) * 2018-12-20 2021-07-30 西达赛奈医疗中心 克拉扎珠单抗用于治疗慢性抗体介导的器官移植物排斥反应

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4162947A1 (en) 2013-11-22 2023-04-12 Takeda Pharmaceutical Company Limited Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
IL273185B2 (en) 2017-09-15 2024-10-01 Cedars Sinai Medical Center C1 esterase inhibitors for use in improving organ function in organ transplantation subjects
WO2019166572A1 (en) * 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
EP4010010A4 (en) * 2019-08-08 2023-08-09 Cedars-Sinai Medical Center METHODS FOR IMPROVING ORGAN FUNCTION
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
WO2022109124A1 (en) * 2020-11-20 2022-05-27 Csl Behring Gmbh Method for treating antibody-mediated rejection
EP4366761A1 (en) 2021-07-09 2024-05-15 Pharming Intellectual Property B.V. Using c1 esterase inhibitor to treat viral infection-related symptoms
WO2024152030A1 (en) * 2023-01-13 2024-07-18 The Uab Research Foundation Crossmatching for porcine xenotransplantation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101437501A (zh) * 2006-03-02 2009-05-20 阿莱克申药物公司 通过抑制补体活性延长同种异体移植物的存活
WO2013041677A1 (en) * 2011-09-24 2013-03-28 Csl Behring Gmbh Combination therapy using immunoglobulin and c1-inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4212278B2 (ja) * 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
CA2654446C (en) 2005-06-07 2014-02-25 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival
CN105188750A (zh) * 2013-03-08 2015-12-23 德国杰特贝林生物制品有限公司 治疗和预防远端缺血-再灌注损伤
RS58351B1 (sr) 2013-03-15 2019-03-29 Shire Viropharma Inc C1-inh kompozicije i postupci za prevenciju i lečenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze
EP4162947A1 (en) * 2013-11-22 2023-04-12 Takeda Pharmaceutical Company Limited Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101437501A (zh) * 2006-03-02 2009-05-20 阿莱克申药物公司 通过抑制补体活性延长同种异体移植物的存活
WO2013041677A1 (en) * 2011-09-24 2013-03-28 Csl Behring Gmbh Combination therapy using immunoglobulin and c1-inhibitor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "A Randomized Double-Blind Placebo-Controlled Pilot", 《CLINICALTRIALS.GOV》 *
ANONYMOUS: "Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal Transplantation", 《CLINICALTRIALS.GOV》 *
JUNCHAO CAI ET AL.: "Humoral theory of transplantation: some hot", 《BRITISH MEDICAL BULLETIN》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113194996A (zh) * 2018-12-20 2021-07-30 西达赛奈医疗中心 克拉扎珠单抗用于治疗慢性抗体介导的器官移植物排斥反应
CN113035369A (zh) * 2021-03-10 2021-06-25 浙江大学 一种肾移植抗感染药物剂量预测模型的构建方法

Also Published As

Publication number Publication date
AU2020200015A1 (en) 2020-01-30
EP3071219A1 (en) 2016-09-28
US20150147319A1 (en) 2015-05-28
ME03318B (me) 2019-10-20
KR102384814B1 (ko) 2022-04-08
CA2930964A1 (en) 2015-05-28
DK3071219T3 (en) 2019-02-25
MX2021000332A (es) 2021-04-13
ES2708655T3 (es) 2019-04-10
KR20210125118A (ko) 2021-10-15
WO2015077543A1 (en) 2015-05-28
MX378834B (es) 2025-03-11
EP3494988B1 (en) 2022-08-03
NZ759187A (en) 2022-08-26
PT3071219T (pt) 2019-02-06
BR112016011499A2 (pt) 2020-10-27
JP2022179637A (ja) 2022-12-02
JP2016537380A (ja) 2016-12-01
JP2019023233A (ja) 2019-02-14
EP3494988A1 (en) 2019-06-12
LT3071219T (lt) 2019-01-10
AU2020200015B2 (en) 2022-03-10
US20180104319A1 (en) 2018-04-19
KR20160079821A (ko) 2016-07-06
US9895428B2 (en) 2018-02-20
HUE041809T2 (hu) 2019-05-28
AU2014352846A1 (en) 2016-06-02
NZ719724A (en) 2022-08-26
EP3071219B1 (en) 2018-11-14
JP2021063141A (ja) 2021-04-22
PL3071219T3 (pl) 2019-04-30
SI3071219T1 (sl) 2019-03-29
SMT201900042T1 (it) 2019-02-28
US20200360495A1 (en) 2020-11-19
HRP20190184T1 (hr) 2019-03-22
JP2019001831A (ja) 2019-01-10
CN111388655A (zh) 2020-07-10
JP6620206B2 (ja) 2019-12-11
RS58343B1 (sr) 2019-03-29
JP6431912B2 (ja) 2018-11-28
SG10201804326SA (en) 2018-06-28
AU2014352846B2 (en) 2019-10-03
KR102312817B1 (ko) 2021-10-13
CY1121298T1 (el) 2020-05-29
MX2016006656A (es) 2016-09-06
EP4162947A1 (en) 2023-04-12

Similar Documents

Publication Publication Date Title
CN105744949A (zh) 用c1-酯酶抑制剂治疗器官移植患者中的抗体介导的排斥的方法
JP5590624B2 (ja) 補体活性を阻害することによる同種移植片の生存の延長
EP2918269A1 (en) Prolongation of survival of an allograft by inhibiting complement activity
US20240139195A1 (en) Methods of treating chronic active antibody-mediated rejection using btk inhibitors
HK40091830A (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
HK40008415A (en) Treatment of antibody-mediated rejection in organ transplant patients with c1- esterase inhibitor
HK40008415B (en) Treatment of antibody-mediated rejection in organ transplant patients with c1- esterase inhibitor
HK1240072A1 (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
HK1229241A1 (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
HK1229241B (en) Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1240072

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160706

WD01 Invention patent application deemed withdrawn after publication